Central Asian Problems of Modern Science and Education


The article presents the data of our studies on cognitive impairment in patients with Parkinson's disease (PD): their characteristics and risk factors, features of clinical manifestations

First Page


Last Page



[1]. Aarsland D., Kurz M.W. // Brain Pathol. – 2010. – Vol. 20. – P. 633–639. [2]. Choi S.H., Jung T.M., Lee J.E. et al. // Neurobiol. of Aging. – 2012. – Vol. 33(7). – P. 1265–1272. [3]. Hughes, A.J. Accuracy of clinical diagnosis of idiopathic Parkinson‘s disease: a clinico-pathological study of 100 cases / A.J. Hughes, S.E. Daniel, L. Kilford, A.J. Lees // J. Neurol. Neurosurg. Psychiatry – 1992. – V. 55. – № 3. – P. 181–184. [4]. Goetz C.G., Poewe W., Rascol O. et al. Movement Disorder Society Task Force report on the Hoehn and Yahr staging scale: status and recommendations. Mov. Disord. 2004; 19: 1020-1028. [5]. R.C.Peterson.,D.S.Knopmn at al., Mild cognitive impairment : ten years later// Arch Neurol. 2009 Dec. 66(12): 1447-1455 [6]. M.Ikeda., H.Kataoka.,et al. Can levodopa prevent cognitive decline in patients with Parkinson‘s disease // J Neurodegener Dis. 2017; 6(2): 9–14. 131 [7]. Sánchez-Castañeda C, Campdelacreu J, Miró J, Juncadella M, Jaumà S, Calopa M. Cognitive improvement after duodenal levodopa infusion in cognitively impaired Parkinson‘s disease patients. Prog Neuropsychopharmacol Biol Psychiatry. 2010;34:250–251.



To view the content in your browser, please download Adobe Reader or, alternately,
you may Download the file to your hard drive.

NOTE: The latest versions of Adobe Reader do not support viewing PDF files within Firefox on Mac OS and if you are using a modern (Intel) Mac, there is no official plugin for viewing PDF files within the browser window.